000			02244 a2200709 4500
005			20250517032112.0
264		0	_c20151117
008			201511s 0 0 eng d
022			_a1365-2249
024	7		_a10.1111/cei.12652 _2doi
040			_aNLM _beng _cNLM
100	1		_aRup, B
245	0	0	_aStandardizing terms, definitions and concepts for describing and interpreting unwanted immunogenicity of biopharmaceuticals: recommendations of the Innovative Medicines Initiative ABIRISK consortium. _h[electronic resource]
260			_bClinical and experimental immunology _cSep 2015
300			_a385-400 p. _bdigital
500			_aPublication Type: Journal Article; Research Support, Non-U.S. Gov't; Review
650	0	4	_aAllergy and Immunology _xstandards
650	0	4	_aDrug Hypersensitivity _ximmunology
650	0	4	_aDrug Industry _xorganization & administration
650	0	4	_aDrugs, Investigational _xadverse effects
650	0	4	_aGuidelines as Topic _xstandards
650	0	4	_aHumans
650	0	4	_aOrganizational Innovation
650	0	4	_aOrganizational Policy
650	0	4	_aReference Standards
650	0	4	_aTerminology as Topic
700	1		_aPallardy, M
700	1		_aSikkema, D
700	1		_aAlbert, T
700	1		_aAllez, M
700	1		_aBroet, P
700	1		_aCarini, C
700	1		_aCreeke, P
700	1		_aDavidson, J
700	1		_aDe Vries, N
700	1		_aFinco, D
700	1		_aFogdell-Hahn, A
700	1		_aHavrdova, E
700	1		_aHincelin-Mery, A
700	1		_aC Holland, M
700	1		_aH Jensen, P E
700	1		_aJury, E C
700	1		_aKirby, H
700	1		_aKramer, D
700	1		_aLacroix-Desmazes, S
700	1		_aLegrand, J
700	1		_aMaggi, E
700	1		_aMaillère, B
700	1		_aMariette, X
700	1		_aMauri, C
700	1		_aMikol, V
700	1		_aMulleman, D
700	1		_aOldenburg, J
700	1		_aPaintaud, G
700	1		_aR Pedersen, C
700	1		_aRuperto, N
700	1		_aSeitz, R
700	1		_aSpindeldreher, S
700	1		_aDeisenhammer, F
773	0		_tClinical and experimental immunology _gvol. 181 _gno. 3 _gp. 385-400
856	4	0	_uhttps://doi.org/10.1111/cei.12652 _zAvailable from publisher's website
999			_c24886467 _d24886467